Scarica l'app Stockscreener
79.33
0.03%
0.02
Dopo l'orario di chiusura:
79.33
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EW Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$79.31
Aprire:
$79.02
Volume 24 ore:
3.15M
Relative Volume:
0.73
Capitalizzazione di mercato:
$46.53B
Reddito:
$5.69B
Utile/perdita netta:
$4.15B
Rapporto P/E:
11.41
EPS:
6.95
Flusso di cassa netto:
$623.10M
1 W Prestazione:
-0.84%
1M Prestazione:
+2.79%
6M Prestazione:
+9.50%
1 anno Prestazione:
+28.24%
Intervallo 1D:
$77.96
$79.73
Intervallo di 1 settimana:
$77.96
$81.88
Portata 52W:
$59.41
$83.00
Edwards Lifesciences Corp Stock (EW) Company Profile
Nome
Edwards Lifesciences Corp
Settore
Industria
Telefono
(949) 250-2500
Indirizzo
ONE EDWARDS WAY, IRVINE, CA
Confronta EW con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
79.33 | 46.52B | 5.69B | 4.15B | 623.10M | 6.95 |
|
ABT
Abbott Laboratories
|
127.29 | 219.63B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
105.41 | 155.22B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
377.79 | 150.09B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
89.34 | 115.62B | 33.54B | 4.66B | 5.19B | 3.62 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-29 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2025-04-24 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Aggiornamento | Stifel | Hold → Buy |
| 2025-01-16 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Downgrade | Jefferies | Buy → Hold |
| 2024-07-31 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-07-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Downgrade | TD Cowen | Buy → Hold |
| 2024-07-25 | Downgrade | Truist | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-05-14 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-02-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2023-11-28 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Overweight |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-03-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Downgrade | Bernstein | Outperform → Underperform |
| 2023-01-30 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Downgrade | Stifel | Buy → Hold |
| 2022-10-28 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Iniziato | Mizuho | Buy |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-29 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Iniziato | Truist | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-03-16 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-27 | Reiterato | Citigroup | Buy |
| 2022-01-27 | Reiterato | Evercore ISI | Outperform |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | Stifel | Buy |
| 2022-01-27 | Reiterato | UBS | Neutral |
| 2021-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-12-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-30 | Reiterato | Deutsche Bank | Hold |
| 2021-07-30 | Reiterato | Jefferies | Buy |
| 2021-07-30 | Reiterato | Morgan Stanley | Overweight |
| 2021-07-30 | Reiterato | Oppenheimer | Outperform |
| 2021-07-30 | Reiterato | Stifel | Buy |
| 2021-07-30 | Reiterato | UBS | Neutral |
| 2021-07-30 | Reiterato | Wells Fargo | Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-04-05 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-11 | Reiterato | Canaccord Genuity | Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Underperform |
| 2020-04-28 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Outperform |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Reiterato | Canaccord Genuity | Buy |
| 2019-09-23 | Iniziato | Piper Jaffray | Overweight |
| 2019-07-24 | Reiterato | BofA/Merrill | Buy |
| 2019-03-18 | Reiterato | Canaccord Genuity | Buy |
| 2019-01-18 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Iniziato | Deutsche Bank | Hold |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-16 | Iniziato | Barclays | Underweight |
| 2018-10-02 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Downgrade | Guggenheim | Buy → Neutral |
Mostra tutto
Edwards Lifesciences Corp Borsa (EW) Ultime notizie
How volatile is Edwards Lifesciences Corporation stock compared to the marketFree Stock Selection - jammulinksnews.com
Is Edwards Lifesciences Corporation a growth stock or a value stockHigh-octane investment gains - jammulinksnews.com
What catalysts could drive Edwards Lifesciences Corporation stock higher in 2025Build wealth with professional market analysis - jammulinksnews.com
Is it the right time to buy Edwards Lifesciences Corporation stockSuperior portfolio returns - jammulinksnews.com
How many analysts rate Edwards Lifesciences Corporation as a “Buy”Strongest growth potential - jammulinksnews.com
What are the technical indicators suggesting about Edwards Lifesciences CorporationMarket-crushing stock picks - jammulinksnews.com
Should I hold or sell Edwards Lifesciences Corporation stock in 2025Real Time Alerts For Fast Growth - jammulinksnews.com
Edwards Lifesciences’ SAPIEN 3 Valve Study: A Real-World Evaluation - TipRanks
Edwards Lifesciences’ PASCAL System: A Promising Update in Tricuspid Valve Repair - TipRanks
Agree To Purchase Edwards Lifesciences At $65, Earn 5.2% Using Options - Nasdaq
How Edwards Lifesciences Corporation stock reacts to Fed policy changesAI Powered High Return Stock Calls Dominate Watchlists - beatles.ru
Edwards Lifesciences’ SAPIEN 3 Study: A Market Game-Changer? - TipRanks
A Quick Look at Today's Ratings for Edwards Lifesciences(EW.US), With a Forecast Between $84 to $100 - 富途牛牛
Edwards Lifesciences Stock (EW) Opinions on Q2 Earnings Beat - Quiver Quantitative
Edwards Lifesciences’ Pivotal Trial: A Game-Changer for Tricuspid Valve Repair? - TipRanks
Edwards Lifesciences Corporation (NYSE:EW) Q2 2025 Earnings Call Transcript - Insider Monkey
Analysts upgrade Edwards as TAVR segment improves - MassDevice
BTIG upgrades Edwards Lifesciences stock to Buy on TAVR segment stability - Investing.com
Edwards Lifesciences prevails in heart valve dispute at the UPC - JUVE Patent
Edwards Lifesciences Insider Makes a Major Stock Move! - TipRanks
Edwards Lifesciences Reports Strong Growth and Raises Guidance - TipRanks
Edwards Lifesciences debuts heart valve failure PSA as Rams training camp begins - Medical Marketing and Media
Edwards Lifesciences stock price target raised to $85 by Bernstein - Investing.com
Edwards Lifesciences stock price target raised to $85 by UBS on strong TAVR sales - Investing.com
Edwards Lifesciences’ SWOT analysis: strong TAVR growth boosts stock outlook - Investing.com
When is Edwards Lifesciences Corporation stock expected to show significant growthExceptional return forecasts - jammulinksnews.com
Edwards Lifesciences (EW) Announces Executive Leadership Change - GuruFocus
Can Edwards Lifesciences Corporation stock recover from recent declineTriple Return With Stability - metal.it
Edwards Lifesciences stock price target raised to $90 by Piper Sandler - Investing.com
Earnings Preview: What To Expect From Edwards Lifesciences' Report - MSN
Edwards Lifesciences Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo.co
Edwards Lifesciences stock price target raised to $84 from $75 at TD Cowen - Investing.com
Edwards Lifesciences stock price target raised to $89 at RBC on growth outlook - Investing.com
JPMorgan Adjusts Edwards Lifesciences (EW) Price Target Followin - GuruFocus
Edwards Lifesciences (EW) Target Price Raised by JP Morgan | EW Stock News - GuruFocus
Edwards Lifesciences sales up nearly 12% in Q2 - MassDevice
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences Corporation Stock Analysis and ForecastPhenomenal returns - PrintWeekIndia
Edwards Lifesciences Q2 EarningsEdwards Lifesciences (NYSE:EW) - Benzinga
Edwards Exec Larry Wood Departs for Procept BioRobotics - Orange County Business Journal
Edwards Lifesciences (EW) Target Price Raised by Baird Analyst | - GuruFocus
Edwards Lifesciences’ MITRIS Valve Study: A Key Development for Investors - TipRanks
Edwards Lifesciences stock reaches 52-week high at 81.86 USD - Investing.com
Edwards Lifesciences Analysts Increase Their Forecasts After Stronger-Than-Expected Q2 Results - Benzinga
Edwards Lifesciences (EW) Surpasses Earnings and Revenue Expecta - GuruFocus
Edwards Lifesciences Q2 2025 Earnings Report - MarketBeat
Edwards Lifesciences (EW) Receives Price Target Upgrade from Deutsche Bank | EW Stock News - GuruFocus
Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW) - Yahoo Finance
Edwards Lifesciences (EW) Receives Price Target Boost from Baird | EW Stock News - GuruFocus
JPMorgan Adjusts Edwards Lifesciences (EW) Price Target Following Strong Q2 Results | EW Stock News - GuruFocus
Edwards loses longtime TAVR leader Larry Wood - Yahoo Finance
Edwards Lifesciences Corp Azioni (EW) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.06%
0.99%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):